Abstract
The publication of the results of LEADER and SUSTAIN-6 trials suggested a possible beneficial effect of the class of GLP-1 receptor agonists on cardiovascular morbidity and mortality. The aim of the present meta-analysis is to collect and synthetize all available evidence on the effect of GLP-1 receptor agonists on cardiovascular events and mortality. A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The principal outcome of this analysis was the effect of GLP-1 receptor agonists on all-cause and cardiovascular mortality, overall (fatal plus nonfatal) myocardial infarction, stroke, and heart failure. Out of 113 trials fulfilling inclusion criteria (mean duration 41.7±38.2weeks), 32, 25, 48, 43 and 32 reported at least one event for all-cause and cardiovascular mortality, overall (fatal plus nonfatal) myocardial infarction, stroke, and heart failure, respectively. In GLP-1 receptor agonist-treated patients, all-cause mortality, cardiova...Continue Reading
Citations
Sep 8, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Jul 22, 2018·Diabetes/metabolism Research and Reviews·Annunziata NuscaGermano Di Sciascio
Aug 30, 2018·Journal of Managed Care & Specialty Pharmacy·Michael HeileMichael Shannon
Oct 25, 2017·Circulation·Yuliya LytvynDavid Z I Cherney
Jan 11, 2019·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F BarkasH Milionis
Feb 28, 2019·Expert Opinion on Drug Safety·Vasilios G AthyrosMichael Doumas
Mar 1, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Cheli Melzer-CohenAvraham Karasik
Jul 3, 2019·Current Vascular Pharmacology·Dimitrios PatouliasAsterios Karagiannis
Feb 25, 2020·European Journal of Preventive Cardiology·Vishnu Priya PulipatiPriyanjali Pulipati
Apr 14, 2020·Cardiology in Review·Srikanth YandrapalliWilliam H Frishman
May 27, 2020·International Journal of Clinical Practice·Raquel Herrera Comoglio, Xavier Vidal Guitart
Mar 10, 2020·Canadian Journal of Physiology and Pharmacology·Chris R TriggleMorley D Hollenberg
Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Jun 2, 2017·Journal of Endocrinological Investigation·M MonamiE Mannucci
Dec 22, 2019·Reviews in Endocrine & Metabolic Disorders·Giovanni CoronaFrancesco Lombardo
Jun 27, 2019·PloS One·Guillaume GrenetFrançois Gueyffier
Jan 4, 2021·Atencion primaria·Domingo Orozco-BeltránJorge Navarro Pérez
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Qi-You DingXiao-Lin Tong
Feb 6, 2020·Current Vascular Pharmacology·Dimitrios PatouliasAsterios Karagiannis
Apr 6, 2021·Andrology·Rossella CannarellaSandro La Vignera
Aug 9, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Edoardo MannucciUNKNOWN SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes
Aug 28, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·Alan J Sinclair, Ahmed H Abdelhafiz
Aug 3, 2019·Clinical Diabetes : a Publication of the American Diabetes Association·Kenneth S HershonOla Odugbesan